AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP issued a shareholder-solicitation notice reminding AARD investors of a securities fraud class action and an October 13, 2026 lead-plaintiff deadline. The complaint alleges Aardvark misled investors about the safety profile and clinical and commercial prospects of its ARD-101 drug candidate spanning the February 2025 IPO through May 2026.
Key figures
- Class period
- Feb 13, 2025 (IPO) and/or Feb 13, 2025 to May 14, 2026
- Lead plaintiff deadline
- October 13, 2026
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.